Neuropsychiatric association of tirzepatide and semaglutide in obesity with and without type 2 diabetes.

“Neuropsychiatric association of tirzepatide and semaglutide in obesity with and without type 2 diabetes. Huang YN(1)(2)(3), Liu KW(1)(2)(3), Li PH(2)(3), Chen JC(2)(3), Meyerowitz-Katz G(4), Su PH(5)(6), Huang CC(7). Author information: (1)Department of Life Science, National Chung Hsing University, Taichung, Taiwan. (2)Department of Pediatrics, Chung Shan Medical University Hospital, Taichung, Taiwan. (3)School of Medicine, Chung Shan Medical University, Taichung, Taiwan. (4)School of Health and Society, University of Wollongong, Wollongong, Australia. (5)Department of Pediatrics, Chung Shan Medical University Hospital, Taichung, Taiwan. ninaphsu@gmail.com. (6)School of Medicine, Chung Shan Medical University, Taichung, Taiwan. ninaphsu@gmail.com. (7)Department of Life Science, National Chung Hsing University, Taichung, Taiwan. cchuang@dragon.nchu.edu.tw. BACKGROUND: Neuropsychiatric outcomes after starting newer anti-obesity medicines remain uncertain in routine care. We evaluate associations between initiation of tirzepatide or semaglutide and incident neuropsychiatric diagnoses in people with obesity, stratified by type 2 diabetes (T2D). METHODS: Using a United States electronic health record network (2020-2025), we identified adults with obesity who newly started tirzepatide or semaglutide and matched them one-to-one to new users of naltrexone-bupropion, phentermine, or phentermine-topiramate. We modeled the time to first recorded diagnosis over 24 months; bariatric surgery recipients were examined as a contextual comparator. Confidence intervals are 95%. RESULTS: Here we show that, versus naltrexone-bupropion, semaglutide is associated with lower hazards of anxiety disorder in adults with T2D (hazard ratio 0.67, 0.51-0.87) and without T2D (0.73, 0.64-0.83), and lower hazards of depression in both strata (with T2D: 0.69, 0.50-0.95; without T2D: 0.53, 0.45-0.61). Tirzepatide versus naltrexone-bupropion is associated with lower hazard ratios for anxiety disorder (with T2D: 0.55, 0.40-0.76; without T2D: 0.78, 0.68-0.89) and depression (with T2D: 0.49, 0.33-0.72; without T2D: 0.57, 0.49-0.66). In adults without T2D, tirzepatide versus semaglutide is associated with higher hazards of anxiety disorder (1.12, 1.06-1.18) and insomnia (1.13, 1.05-1.21). CONCLUSIONS: Initiation of tirzepatide and semaglutide is associated with differing hazard patterns across prescription comparators, with bariatric surgery providing additional context. These findings inform monitoring and shared decisions, while remaining subject to residual confounding and diagnosis misclassification. Plain Language Summary: People with obesity often use newer medicines such as tirzepatide or semaglutide, but real-world information on mental and nerve health after starting them is limited. Using U.S. electronic health records, we compared adults with obesity who started tirzepatide or semaglutide with adults who started other prescription weight-loss medicines. We followed people for up to two years and recorded new diagnoses of anxiety and related conditions. In several comparisons, tirzepatide and semaglutide were associated with lower rates of some mental health diagnoses than naltrexone–bupropion. Among people without type 2 diabetes, tirzepatide was associated with higher rates of anxiety and insomnia than semaglutide. These findings may support monitoring and shared decisions, but they do not show cause and should be confirmed in studies with standardized assessments. © 2026. The Author(s). Conflict of interest statement: Competing interests: The authors declare no conflicts of interest. The funders had no role in the study design, conduct, data analysis, interpretation, or manuscript preparation, and no personal or financial relationships influenced the work.”